VAXCYTE, INC. (PCVX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -298.40M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-298.40M | (m) |
| 2026-03-31 | (m) | $-180.67M | (m) |
| 2025-12-31 | (m) | $-766.63M | (m) |
| 2025-09-30 | (m) | $-657.20M | (m) |
| 2025-06-30 | (m) | $-547.50M | (m) |
| 2025-03-31 | (m) | $-509.63M | (m) |
| 2024-12-31 | (m) | $-463.93M | (m) |
| 2024-09-30 | (m) | $-507.65M | (m) |
| 2024-06-30 | (m) | $-497.19M | (m) |
| 2024-03-31 | (m) | $-436.82M | (m) |
| 2023-12-31 | (m) | $-402.27M | (m) |
| 2023-09-30 | (m) | $-299.51M | (m) |
| 2023-06-30 | (m) | $-264.77M | (m) |
| 2023-03-31 | (m) | $-244.96M | (m) |
| 2022-12-31 | (m) | $-223.49M | (m) |
| 2022-09-30 | (m) | $-174.00M | (m) |
| 2022-06-30 | (m) | $-142.70M | (m) |
| 2022-03-31 | (m) | $-117.84M | (m) |
| 2021-12-31 | (m) | $-100.08M | (m) |
| 2021-09-30 | (m) | $-92.25M | (m) |
| 2021-06-30 | (m) | $-86.65M | (m) |
| 2021-03-31 | (m) | $-83.30M | (m) |
| 2020-12-31 | (m) | $-89.22M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-50.27M | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
| 2018-12-31 | (m) | $-29.48M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |